Sort   by:  
 Page size 
TranscriptomicsRNA-seq of human breast cancer cell line MCF7, T47D and CAMA-1 treated that are naïve and resistant to capivasertib and have been treated with acute capivasertib, continuous capivasertib and DMSO
MCF7, T47D and CAMA-1 cell lines were treated with long-term (continuous) capivasertib to induce resistant cell-lines (T47D P1, MCF7 P1 and CAMA-1 P1). The naïve (or parental) cell lines had RNAseq sequencing at treatment with DMSO and treatment with capivasertib. Resistant cell lines had RNAseq seq...
ORGANISM(S): Homo sapiens 
2026-05-25 | E-MTAB-16414 | biostudies-arrayexpress
TranscriptomicsCRISPR screen exploring resistance to AKTi (Capivasertib) in ER+ Breast Cancer in MCF7, T47D and CAMA-1 cell lines
A genome-wide CRISPR-Cas9 knockout screen was performed in the breast cancer cell lines T47D, MCF7, and CAMA-1 to identify genes modulating sensitivity and resistance to capivasertib, a selective AKT inhibitor. Cells were transduced with a CRISPR library, followed by treatment with capivasertib or v...
ORGANISM(S): Homo sapiens 
2026-05-25 | E-MTAB-16438 | biostudies-arrayexpress
GenomicsRNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)
RNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)
PRJNA609909 | ENA
TranscriptomicsRNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination
T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and ca...
ORGANISM(S): Homo sapiens 
2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress
UnknownA phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC7217345 | biostudies-literature
ProteomicsmTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours
Capivasertib is a potent selective inhibitor of AKT. It was recently FDA-approved in combination with fulvestrant to treat HR+, HER2-negative breast cancers with certain genetic alteration(s) activating the PI3K pathway. In Phase I trials, heavily pre-treated patients with tumours selected for activ...
ORGANISM(S): Homo sapiens (Human) 
2024-10-17 | PXD052949 | Pride
Pi3k/akt/mtor signaling pathway in cancer  tyrosine kinase inhibitors  capivasertib (azd5363)  precision medicine  genetic mutations  breast cancer  gynecological cancer  targeted proteomics  global proteomics  translational control 
TranscriptomicsRNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)
First line treatment with AKT inhibitors combined with paclitaxel improves outcomes of metastatic TNBC, especially in tumors that harbor mutations in PTEN/PIK3CA/AKT1. In this work, we refine the composite response biomarker to AZD5363 in this setting, which is relevant to inform the clinical develo...
ORGANISM(S): Homo sapiens 
2020-06-30 | GSE144794 | GEO
GenomicsPhase Ib of olaparib and capivasertib
Background: Combining poly(ADP-ribose) polymerase (PARP) with phosphatidylinositol-3-kinase (PI3K) pathway inhibitors is supported by strong preclinical rationale. We sought to assess safety and a recommended phase 2 dose (RP2D) for the PARPi olaparib combined with the AKT inhibitor, capivasertib,...
EGAS00001004930 | EGA
Unknown"The emerging role of capivasertib in breast cancer".
Not available
S-EPMC9011110 | biostudies-literature
UnknownBEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Not available
S-EPMC6551452 | biostudies-literature
Sort   by:  
 Page size